scholarly journals CCN4 shifts melanoma cells from a fragile proliferative state to a resilient metastatic state

2018 ◽  
Author(s):  
Wentao Deng ◽  
Audry Fernandez ◽  
Sarah L. McLaughlin ◽  
David J. Klinke

ABSTRACTWhile deregulated intracellular signaling initiates melanoma, intercellular crosstalk within the tumor microenvironment, often coordinated by soluble factors, is essential for melanoma progression and metastasis. One such secreted matricellular protein, cellular communication network factor 4 (CCN4), stimulates metastasis in other malignancies. Here, we report that CCN4 expression is associated progressively with reduced overall survival in patients with primary melanomas. To reveal the roles of CCN4 in melanoma progression, we used mouse melanoma models and knocked outCcn4using a homology-directed repair CRISPR/CAS9 system to generate pools ofCcn4-knockout cells.In vitroassays supported previous findings using clones generated using a double nickase-based CRISPR/CAS9 system that CCN4 promoted an epithelial – mesenchymal-like transition in melanoma cells and stimulated invasion and metastasis. We also found that, whileCcn4knockout enhanced cell growth in optimal 2D culture conditions, the knockout suppressed certain cell survival signaling pathways and rendered cells less resistant to stress conditions. Tumor cell growth assays at sub-optimal conditionsin vitro, quantitative analysis of tumor growth assaysin vivo,and transcriptomics analysis of human melanoma cell lines suggested that CCN4 repressed cell growth and simultaneously enhanced cell survival. The collective role of CCN4 suggests a potential therapeutic target for limiting metastatic invasion in melanoma and a biomarker for metastatic potential.

Biomedicines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 96
Author(s):  
István Szász ◽  
Viktória Koroknai ◽  
Vikas Patel ◽  
Tibor Hajdú ◽  
Tímea Kiss ◽  
...  

HA15 is a new anti-melanoma drug that triggers endoplasmic reticulum (ER) stress and causes deleterious effects on melanoma cell viability due to autophagy and apoptosis, regardless of driver mutations or drug resistance. In this study, we investigated the effect of HA15 on the viability/proliferation of BRAFV600E-mutant melanoma cells using different culture conditions. In contrast to the published data, we did not detect significant melanoma cell death under normal culture conditions using HA15 treatment. Indeed, only cells that were cultured under long-term starvation conditions were sensitive to the drug. Quantitative measurements of ER stress and autophagy markers showed that the compound HA15 does not trigger stress alone but synergistically enhances ER stress under starvation conditions. Importantly, we observed that the viability of normal melanocytes decreased significantly with treatment, even at low HA15 concentrations. Finally yet importantly, we were able to generate HA15-resistant cell lines, which failed by Cerezo et al. In summary, HA15 only influences the viability of cells that are starved for several hours before and during treatment. However, this in vitro setting is far from the in vivo conditions. In addition, our data clearly show that melanoma cells can acquire HA15 resistance. Further studies are needed to prove that HA15 is an effective anti-cancer agent.


2021 ◽  
Author(s):  
Kenji F Shoji ◽  
Elsa Bayet ◽  
Dahiana Le Devedec ◽  
Aude Mallavialle ◽  
Severine Marionneau-lambot ◽  
...  

Discovery of therapeutic targets against metastasis is of primary importance since being the main cause of cancer-related death. Deregulation of calcium homeostasis has been involved in numerous cellular metastatic behaviors, although the molecular determinants supporting these processes remain often unclear. Here, we showed that the expression of the plasma membrane TRPV2 calcium channel is a prominent feature in melanoma progression and dissemination. In fact, TRPV2 activity was sufficient to confer an invasive phenotype to non-invasive melanoma cells. Conversely, the invasive and migratory potential of highly metastatic melanoma cells was abolished upon TRPV2 silencing. Mechanistically, TRPV2 supports melanoma cells aggressiveness by being a new regulator of the calpain-dependent maturation of focal adhesion, and actin cytoskeleton remodeling. Finally, TRPV2 overexpression is a marker of advanced malignancy and bad prognosis in human melanoma tumor samples. Altogether, TRPV2-induced Ca2+ signaling orchestrates in vitro motility and invasiveness of melanoma cells, as well as in vivo metastatic melanoma tumors dissemination.


2020 ◽  
Author(s):  
Yumei Li ◽  
Fan Chen ◽  
Weiyu Shen ◽  
Bifei Li ◽  
Ning Zheng ◽  
...  

Abstract BackgroundMetastasis is the cause of most fatalities in cancer patients and is poorly understood. Discovery of the underlying determinant and regulatory networks implicated in the cancer cell metastasis is urgently needed. MethodsThe expression pattern of nucleolar protein 7 (NOL7) was examined by IHC in clinic melanoma samples. Loss-of-function in melanoma cells was achieved through siRNA and CRISPR/Cas9 system. Assays for proliferation, apoptosis and aggressiveness were performed for functional verification. Immunoblotting and qRT-PCR were used to measure the alterations in proteins and mRNA. Orthotopic xenograft nude mouse model was established to assess the effects of NOL7 on melanoma tumorigenicity and metastatic potential.ResultsNOL7 expression was increased with melanoma progression. Abrogation of NOL7 expression led to the dysfunction of malignant behaviors including proliferation, invasion, and anoikis-resistance of melanoma cells in vitro. Depletion of NOL7 expression suppressed melanoma growth and metastasis in vivo. Mechanistically, NOL7 was found to be induced by HIF-1ɑ under hypoxic condition and inhibition of NOL7 reduced the phosphorylation of AKT and ERK protein. ConclusionThis study revealed the cancer-promoting activity of NOL7 in melanoma cells and identified a novel regulatory mechanism of HIF-1ɑ/NOL7/PI3K/AKT/ERK axis in melanoma. NOL7 can function as a novel alert marker and therapeutic target for melanoma treatment.


2020 ◽  
Author(s):  
Alexander Teichmann ◽  
Jing Jia ◽  
Lanyang Gao ◽  
Danli Zhu ◽  
Qin Wang ◽  
...  

Abstract Background: Increasing evidence suggests that deubiquitinase USP7 participates in tumor progression by various mechanisms and serves as a potential therapeutic target. However, its functional role in melanoma remains elusive and needs to be investigated. Methods: The down-regulation of USP7 in A375 human melanoma cells was determined by high resolution liquid chromatography mass spectrometry (LC-MS/MS). The effects of USP7 expression on proliferation and apoptosis of melanoma cells were examined by western blot, Immunohistochemical and flow cytometry. Further study knock-down of USP7 in A375 cell lines, especially knockout USP7 using CRISPR-Cas9, verified USP7 regulate cell proliferation in vivo and in vitro .Western blot and qRT-PCR, Immunofluorescence were performed to investigate the mechanisms by which USP7 mediated melanoma growth through regulating the PI3K/Akt/FOXO pathways activity Results: Proteomic and western blotting analysis show that inhibition of USP7 increases expression of PRKAB1, CASP7, and PPP2R3A, attenuates expression of ATP6V0C and PEX11B. Furthermore, ATP6V0C and PEX11B are proposed to be the substrate for USP7 function. Conclusions: Our findings demonstrate that PI3K/Akt/FOXO and AMPK signaling pathways can be regulated by USP7 during melanoma progression and provide USP7 as an attractive anticancer target for melanoma.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2839-2839
Author(s):  
Jessie-Farah Fecteau ◽  
Davorka Messmer ◽  
Suping Zhang ◽  
Bing Cui ◽  
Liguang Chen ◽  
...  

Abstract Abstract 2839 The tumor microenvironment may play an important role in the growth and/or survival of leukemia cells of patients (pts) with chronic lymphocytic leukemia (CLL). Studies on the interaction of CLL cells with the microenvironment have been facilitated by our capacity to culture accessory cells in vitro. However, the conditions for culturing such cells in ambient oxygen(O2) at 21% are different than those present in lymphoid tissues which have O2 concentrations ranging from 1–7%. The difference between in vivo and in vitro O2 tensions might influence the biology of leukemia accessory cells. To examine this, we studied the effect(s) of O2 tension on our ability to propagate mesenchymal stromal cells (MSCs) from marrow aspirates of pts with CLL. Equal numbers of fresh or viably frozen marrow mononuclear cells were seeded in DMEM with 10% FBS into separate flasks for culture at 37° C in incubators at atmospheric O2 (Atmos-O2) or at 5% O2 (physiologic; Phys-O2), both with 5% CO2. The cells were monitored for viability and growth over time. We found that only Phys-O2 tension allowed for the generation and long-term expansion of MSCs. Out of the 6 pts tested, 3 developed virtually no MSCs (<10 cells), and 3 generated less than 6×104 MSCs (ranging from 2±1×104 to 6±1×104) in Atmos-O2 after 47±7 days in vitro. In contrast, high numbers of MSCs developed in Phys-O2 for all 6 pts, ranging from 45±8×104 to 80×104 cells, resulting in highly significant differences in yields between the 2 culture conditions (p<0.01). Moreover, the MSCs generated in Phys-O2 continued to proliferate over time, whereas MSCs in Atmos-O2 did not. Under Phys-O2, MSCs were successfully expanded from marrow aspirates of 16 out of 18 CLL pts. The morphology and phenotype of the MSCs generated were similar to that of healthy MSCs, expressing CD29, CD44, CD105 and D7-FIB, and lacking expression of CD14, CD31, CD34, or CD45. We next examined whether the differences in cell yields between the two culture conditions could be the result of compromised MSC proliferation in Atmos-O2. To address this, MSCs generated in Phys-O2 were seeded into separate flasks and exposed to Atmos-O2 or Phys-O2 and proliferation was monitored by BrdU incorporation and viable cell counts. We found that MSCs seeded in Atmos-O2 proliferated significantly less well than MSCs in Phys-O2 (n=3). However, MSC viability was not significantly affected by the change in O2 tension, suggesting that replicative senescence could be induced in MSCs exposed to Atmos-O2. To test this hypothesis, MSCs generated in Phys-O2 were seeded separately under Atmos-O2 or Phys-O2 and stained for the senescence-associated beta-galactosidase (SA-B-Gal) marker. We found a significant increase in the fraction SA-B-gal+ MSCs exposed to Atmos-O2 compared to Phys-O2 (70±18% vs. 13±5%; p<0.0001). MSC morphology in Atmos-O2 was also consistent with senescence, marked by a wide-spread cytoplasm and enlarged nucleus. The cell cycle regulator p16INK4 also was distinctively induced in MSCs exposed to Atmos-O2 compared to Phys-O2 (n=2), consistent with its role in inhibiting cell cycle progression and mediating senescence. We next ask if a disruption of the redox balance plays a role in MSC biology modulated by O2, using the free radical scavenger beta-mercaptoethanol (BME). MSCs generated in Phys-O2 were seeded separately under Phys-O2 or Atmos-O2 +/− BME. We observed that MSC proliferation in Atmos-O2 was restored by the addition of BME to the levels observed in Phys- O2 using BrdU incorporation (n=3). However, in a similar context, BME did not restore MSC expansion in Atmos-O2 measured by viable cell counts, or in the generation of MSCs in Atmos-O2 when added at culture initiation (n=2), suggesting that redox balance disruption is not the main mechanism by which high O2 tension affects MSC biology. We finally evaluated whether co-cultures of CLL cells and MSCs in Phys-O2 and Atmos-O2 tensions equally support CLL cell survival. We found that CLL cell survival was significantly enhanced when co-cultured in Phys-O2 compared to Atmos-O2 after 17 days (87±15% vs 44±17% viable cells; p<0.0001). These results suggest that Phys-O2 tension is not only critical to generate MSCs in vitro, but it also has a profound impact on the biology of these accessory cells, which in turn affects the survival of the leukemic cells. Studies conducted under Phys-O2 tension might further our understanding of the mechanisms governing CLL cell survival in vivo. Disclosures: No relevant conflicts of interest to declare.


2006 ◽  
Vol 175 (4S) ◽  
pp. 257-257
Author(s):  
Jennifer Sung ◽  
Qinghua Xia ◽  
Wasim Chowdhury ◽  
Shabana Shabbeer ◽  
Michael Carducci ◽  
...  

1998 ◽  
Vol 79 (05) ◽  
pp. 1041-1047 ◽  
Author(s):  
Kathleen M. Donnelly ◽  
Michael E. Bromberg ◽  
Aaron Milstone ◽  
Jennifer Madison McNiff ◽  
Gordon Terwilliger ◽  
...  

SummaryWe evaluated the in vivo anti-metastatic activity of recombinant Ancylostoma caninum Anticoagulant Peptide (rAcAP), a potent (Ki = 265 pM) and specific active site inhibitor of human coagulation factor Xa originally isolated from bloodfeeding hookworms. Subcutaneous injection of SCID mice with rAcAP (0.01-0.2 mg/mouse) prior to tail vein injection of LOX human melanoma cells resulted in a dose dependent reduction in pulmonary metastases. In order to elucidate potential mechanisms of rAcAP’s anti-metastatic activity, experiments were carried out to identify specific interactions between factor Xa and LOX. Binding of biotinylated factor Xa to LOX monolayers was both specific and saturable (Kd = 15 nM). Competition experiments using antibodies to previously identified factor Xa binding proteins, including factor V/Va, effector cell protease receptor-1, and tissue factor pathway inhibitor failed to implicate any of these molecules as significant binding sites for Factor Xa. Functional prothrombinase activity was also supported by LOX, with a half maximal rate of thrombin generation detected at a factor Xa concentration of 2.4 nM. Additional competition experiments using an excess of either rAcAP or active site blocked factor Xa (EGR-Xa) revealed that most of the total factor Xa binding to LOX is mediated via interaction with the enzyme’s active site, predicting that the vast majority of cell-associated factor Xa does not participate directly in thrombin generation. In addition to establishing two distinct mechanisms of factor Xa binding to melanoma, these data raise the possibility that rAcAP’s antimetastatic effect in vivo might involve novel non-coagulant pathways, perhaps via inhibition of active-site mediated interactions between factor Xa and tumor cells.


The role of vitamin D is implicated in carcinogenesis through numerous biological processes like induction of apoptosis, modulation of immune system inhibition of inflammation and cell proliferation and promotion of cell differentiation. Its use as additional adjuvant drug with cancer treatment may be novel combination for improved outcome of different cancers. Numerous preclinical, epidemiological and clinical studies support the role of vitamin D as an anticancer agent. Anticancer properties of vitamin D have been studied widely (both in vivo and in vitro) among various cancers and found to have promising results. There are considerable data that indicate synergistic potential of calcitriol and antitumor agents. Possible mechanisms for modulatory anticancer activity of vitamin D include its antiproliferative, prodifferentiating, and anti-angiogenic and apoptic properties. Calcitriol reduces invasiveness and metastatic potential of many cancer cells by inhibiting angiogenesis and regulating expression of the key molecules involved in invasion and metastasis. Anticancer activity of vitamin D is synergistic or additive with the antineoplastic actions of several drugs including cytotoxic chemotherapy agents like paclitaxel, docetaxel, platinum base compounds and mitoxantrone. Benefits of addition of vitamin D should be weighed against the risk of its toxicity.


Sign in / Sign up

Export Citation Format

Share Document